These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 24497930)

  • 21. Covariation between plasma phosphate and daytime cortisol in early Parkinson's disease.
    Håglin L; Bäckman L
    Brain Behav; 2016 Dec; 6(12):e00556. PubMed ID: 28031994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson's disease and vascular parkinsonism.
    Zhang L; Yan J; Xu Y; Long L; Zhu C; Chen X; Jiang Y; Yang L; Bian L; Wang Q
    PLoS One; 2011 Apr; 6(4):e19333. PubMed ID: 21556377
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and risk factors for visual hallucinations in Chinese patients with Parkinson's disease.
    Zhu J; Shen B; Lu L; Lan W; Pan Y; Zhang L; Dong J; Wang M; Zhang L
    J Neurol Sci; 2017 Jan; 372():471-476. PubMed ID: 27823833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychiatric symptoms screening in the early stages of Parkinson's disease.
    Bugalho P; da Silva JA; Cargaleiro I; Serra M; Neto B
    J Neurol; 2012 Jan; 259(1):124-31. PubMed ID: 21691730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delusions, illusions and hallucinations in epilepsy: 2. Complex phenomena and psychosis.
    Elliott B; Joyce E; Shorvon S
    Epilepsy Res; 2009 Aug; 85(2-3):172-86. PubMed ID: 19442490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Influencing factors of visual hallucinations in patients with Parkinson's disease and its relationship with sleep disorders].
    Wu DD; Li SH; Jin LY; Jin Y; Cui YY; Zhao H; Liu HJ; Ma XX; Su W; Chen HB
    Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(13):1016-20. PubMed ID: 27055793
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression.
    Morgante L; Colosimo C; Antonini A; Marconi R; Meco G; Pederzoli M; Pontieri FE; Cicarelli G; Abbruzzese G; Zappulla S; Ramat S; Manfredi M; Bottacchi E; Abrignani M; Berardelli A; Cozzolino A; Paradiso C; De Gaspari D; Morgante F; Barone P;
    J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):76-82. PubMed ID: 21836035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications.
    Stowe R; Ives N; Clarke CE; Deane K; ; Wheatley K; Gray R; Handley K; Furmston A
    Cochrane Database Syst Rev; 2010 Jul; (7):CD007166. PubMed ID: 20614454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study.
    Aarsland D; Larsen JP; Cummins JL; Laake K
    Arch Neurol; 1999 May; 56(5):595-601. PubMed ID: 10328255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study.
    Rascol O; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Fabbri M; Meissner WG; Rachdi A; Tison F; Perez-Lloret S;
    Drugs Aging; 2020 Mar; 37(3):215-223. PubMed ID: 31919803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subthalamic Nucleus Deep Brain Stimulation Modulate Catecholamine Levels with Significant Relations to Clinical Outcome after Surgery in Patients with Parkinson's Disease.
    Yamamoto T; Uchiyama T; Higuchi Y; Asahina M; Hirano S; Yamanaka Y; Kuwabara S
    PLoS One; 2015; 10(9):e0138462. PubMed ID: 26394059
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profiling the most elderly parkinson's disease patients: Does age or disease duration matter?
    Virameteekul S; Phokaewvarangkul O; Bhidayasiri R
    PLoS One; 2021; 16(12):e0261302. PubMed ID: 34937068
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms.
    Lee AH; Weintraub D
    Mov Disord; 2012 Jun; 27(7):858-63. PubMed ID: 22674352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hallucinations in Parkinson's disease--a study of forty three patients.
    Gupta M; Singh G; Khwaja GA; Mehndiratta MM
    J Assoc Physicians India; 2004 Sep; 52():703-6. PubMed ID: 15839446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease.
    Merims D; Shabtai H; Korczyn AD; Peretz C; Weizman N; Giladi N
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1447-53. PubMed ID: 15480845
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hallucinations, delusions, and nocturnal events in 152 Parkinson's patients: a regional survey].
    Bailbé M; Karolewicz S; Neau JP; Dumas P; Gil R;
    Rev Neurol (Paris); 2002 Feb; 158(2):203-10. PubMed ID: 11965176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for visual hallucinations in patients with Parkinson's disease.
    Gama RL; de Bruin VM; de Bruin PF; Távora DG; Lopes EM; Jorge IF; Bittencourt LR; Tufik S
    Neurol Res; 2015 Feb; 37(2):112-6. PubMed ID: 25002179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs.
    Poletti M; Logi C; Lucetti C; Del Dotto P; Baldacci F; Vergallo A; Ulivi M; Del Sarto S; Rossi G; Ceravolo R; Bonuccelli U
    J Clin Psychopharmacol; 2013 Oct; 33(5):691-4. PubMed ID: 23857310
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of switching from dopamine agonists to zonisamide on psychiatric and motor symptoms in patients with Parkinson's disease].
    Abe T; Maruyama H
    Rinsho Shinkeigaku; 2021 Jul; 61(7):449-455. PubMed ID: 34148934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.